Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway (Cancer Cell International, (2020), 20, 1, (97), 10.1186/s12935-020-01186-y)

Xuejiao Liu, Yiming Tu, Yifeng Wang, Di Zhou, Yulong Chong, Lin Shi, Guanzheng Liu, Xu Zhang, Sijin Wu, Huan Li, Shangfeng Gao, Mingshan Niu, Rutong Yu*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

https://doi.org/10.1186/s12935-020-01186-y. The Editor-in-Chief has retracted this article at the authors’ request. After publication, concerns were raised regarding the data included in the figures. Specifically: Fig. 1e 0 Gy images appear to be assembled incorrectly, and the EdU images for 0.125 and 0.25 µM S109 appear highly similar; Fig. 2c 0.25 µM 6 Gy image appears highly similar to Fig. 1i (C6 cells, 25 µM GDC-0449) of another article [1] from the same author group; Fig. 4b 0 mg/kg S109 10 Gy Day 10 (2nd mouse) and Day 18 (2nd mouse) images appear highly similar; Fig. 4e 0 mg/kg S109 10 Gy and 50 mg/kg S109 0 Gy images appear to overlap. The authors have stated that incorrect images were included in the figure panels during figure preparation. Although the authors believe that these issues do not affect the conclusions of the study, they requested to retract the article to prevent any potential confusion or misinterpretation by readers. Xuejiao Liu stated on behalf of all authors that all authors agree to this retraction.

Original languageEnglish
Article number320
JournalCancer Cell International
Volume24
Issue number1
DOIs
Publication statusPublished - Dec 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway (Cancer Cell International, (2020), 20, 1, (97), 10.1186/s12935-020-01186-y)'. Together they form a unique fingerprint.

Cite this